What are Ozempic teeth? The silent side effect of weight loss drug that could harm your smile
Tired of too many ads? go ad free now
As terms like Ozempic face and Ozempic butt gains prominence, dentists are seeing a new troubling trend emerge which is being termed as Ozempic teeth.
Patients on GLP-1 drugs like Ozempic are reporting unexpected dental woes from dry mouth and bad breath to sudden cavities and gum disease. Experts are now warning that the very mechanisms that help these medications curb appetite may also be disrupting the delicate balance that keeps your teeth and gums healthy.
What are Ozempic teeth?
Ozempic teeth refers to a range of dental issues people on GLP-1 medications have been reporting such as dry mouth, bad breath, gum disease and tooth decay.
The drugs are known to suppress appetite which means being on Ozempic could stimulate less saliva flow which can affect lubrication of mouth and throat. According to Cleveland Clinic, saliva also helps protect the teeth from cavity-causing bacteria.
'Anecdotal reports suggest that Ozempic and similar weight-loss drugs may cause dry mouth,' cosmetic dermatologist Dr.
Michele Green told the Daily Mail.
'Ozempic might reduce saliva production, diminishing the mouth's natural ability to cleanse teeth.'
This can affect dental health and cause serious damage to the teeth.
'Saliva is crucial for protecting teeth, as it helps remove food particles, neutralizes acids produced by bacteria in the mouth and provides essential minerals that strengthen tooth enamel,' Green told the Daily Mail.
Tired of too many ads? go ad free now
'When saliva levels are insufficient, the risk of cavities and tooth decay significantly increases.'
Nausea and diarrhea can affect dental health
Dentist Dr Victoria Holden told the Independent that gastrointestinal issues like nausea, diarrhea and vomiting which are common side effects of Ozempic could also be problematic for your dental health.
'The stomach is very acidic, and if the patients are having that acid come up into their mouth, then it really is quite damaging to the teeth,' Dr Holden said.
Drinking lots of water, eating a balanced diet, and practicing good dental hygiene can help you deal with Ozempic teeth.
Keeping your dentist informed about being on the obesity medication could also help them advise you better on Ozempic teeth.
Inside Ozempic: Does the drug really help in weight loss and what are its possible side effects?
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
an hour ago
- Business Standard
Sun Pharma announces top-line results of tildrakizumab 100 mg Phase 3 studies
For treatment of active psoriatic arthritis Sun Pharmaceutical Industries announced top-line results from two Phase 3 clinical studies evaluating the efficacy and safety of tildrakizumab 100 mg (ILUMYA) administered over 24 weeks for treatment of active psoriatic arthritis. Treatment with tildrakizumab 100 mg (ILUMYA) resulted in greater improvements in PsA signs and symptoms at Week 24 compared to treatment with placebo. Both the INSPIRE-1 and INSPIRE-2 studies achieved the primary endpoint, with a higher proportion of patients in the INSPIRE-1 and INSPIRE-2 studies treated with tildrakizumab achieving ACR20 responses at week 24, compared to those receiving placebo (p < 0.05). "We are excited to share that both the INSPIRE-1 and INSPIRE-2 clinical trials have successfully met their primary endpoints. These top-line results reinforce the therapeutic potential of ILUMYA as a treatment option for patients with active psoriatic arthritis. We extend our sincere gratitude to the patients, healthcare professionals and administrators whose contributions made the studies possible. We look forward to sharing the complete clinical data in the near future, said Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Specialty Development at Sun Pharma.
Time of India
12 hours ago
- Time of India
Weight loss drugs could improve polycystic ovary syndrome: All you need to know
Image credits: Getty Images According to the Endocrine Society, an estimated 5-6 million women of reproductive age in the U.S. are affected by PCOS, which is frequently underdiagnosed. Caused by high levels of testosterone and androgens, polycystic ovary syndrome leads to symptoms such as irregular periods, excess hair growth, acne, insulin resistance and more. It is one of the leading causes of infertility and is strongly linked to metabolic issues, leading to weight gain and hormonal imbalance. One would think a condition affecting such a huge number of women would have a treatment and medicine ready by now. However, when it comes to PCOS, a condition which also leads to other damaging conditions such as obesity and Type 2 diabetes, there's no standard treatment. Mostly, women opt for birth control, lifestyle changes and a diabetes drug, Metformin, which helps with some symptoms. However, now, a ray of light has come around in the form of popular weight loss drugs that are shockingly helping with improving PCOS. One of the many women who have experienced a positive result is Grace Hamilton, 27, who earlier had to battle problems like hair loss, heavy periods, inconsistent menstrual cycles, mental health problems and sudden weight loss. After getting diagnosed with PCOS, she tried birth control and lifestyle changes, only to see limited improvements. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas in Dubai | Search Ads Get Info Undo It was in 2024 when Hamilton joined a trial examining the effects of GLP-1 drugs in PCOS patients. In October, she received her first dose of semaglutide, the active ingredient in Wegovy and Ozempic. The results, as she said to CNBC were almost immediate with resumed periods, hair regrowth and improvement in depression and anxiety. 'I'm so glad that I stuck with it because it was just clear as day that it was the missing link for me,' said Hamilton, adding that she also maintained a diet and exercise regimen. Are weight loss drugs really the answer? Image credits: Getty Images Some health experts see huge potential in GLP-1, particularly in their effect on improving weight loss and insulin sensitivity. 'The unmet need is massive,' said Dr. Melanie Cree, a pediatric endocrinologist at Children's Hospital Colorado, to CNBC. 'Primary therapies used for PCOS symptoms haven't changed in nearly 50 years.' Cree has been studying the effects of GLP-1 in adolescents with PCOS for more than 10 years. She previously studied the oral form of semaglutide and now has an ongoing clinical trial with the injectable version, which worked well for patients like Hamilton. Her trial began in 2023 with girls and women between the ages of 12-35 with obesity and PCOS who are on or off Metformin. Semaglutide was administered to the patients for 10 months to analyse their weight loss, metabolic changes and reproductive functions. The initial data included 11 women who completed the 10-month trial and were not on Metformin. 8 of these lost more than 10% of their body weight and saw a reduction in their hormone levels. Six of the 8 women even reported more regular periods. However, her study group is much smaller compared to the studies done on the popular weight loss drugs, and the results did not show similar effects on everyone. Here, the importance of conducting larger and longer trials on the same is important. This is because the potential for GLP-1 to cause relief in various PCOS symptoms remains. In previous studies, it has been found that in adults with PCOS, losing even 5% of body weight can improve insulin sensitivity. Thus, the body can respond better to insulin, and the pancreas doesn't need to pump out more insulin to keep the blood sugar in check. This will lower insulin levels, in turn lowering the production of testosterone and reducing symptoms of irregular period, acne and excess hair growth. Semaglutide not only improves insulin sensitivity but also reduces appetite by slowing how quickly the food leaves the stomach, prompting the pancreas to release insulin when the blood sugar is high and suppressing the release of a hormone that elevates blood sugar. Not only trials, a recent survey of 1700 people by the birth control app Natural Cycles, revealed that 64% of women with PCOS who took GLP-1 reported more predictable periods, and 20% reported that their bleeding days were shorter. Now, what is needed is a much larger research study on the subject to analyse its effects and see if it can be administered to all women with PCOS.
Time of India
a day ago
- Time of India
Ozempic and Wegovy may cut dementia risk by 45% and manage diabetes, study finds
Source: Reuters A groundbreaking study has revealed that GLP-1 receptor agonists—including popular weight-loss and diabetes drugs like Ozempic, Wegovy, and Mounjaro- may significantly reduce the risk of developing dementia. The analysis, conducted by Irish researchers and published in JAMA Neurology , involved data from over 164,000 participants and found that these medications reduced the risk of memory-robbing disorders by up to 45 per cent. These findings not only open new avenues for neurological protection but also position GLP-1 drugs as powerful tools in both metabolic and cognitive health management. Study links GLP-1 drugs like Ozempic and Mounjaro to lower dementia risk Researchers from the University of Galway reviewed 26 clinical trials involving 164,531 individuals—65% of whom were men, with an average age of 64. The participants were followed for an average of 31 months. The key discovery: patients taking GLP-1 agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) were 45% less likely to develop dementia compared to those on other glucose-lowering medications. Dr. Catriona Reddin, senior study author, said, 'Our findings suggest that GLP-1 receptor agonists, in particular, may have a protective effect on brain health.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo How GLP-1 agonists may protect against dementia Although the exact mechanism remains under investigation, researchers propose several pathways through which GLP-1 medications could shield the brain: Reduced neuroinflammation: These drugs may lower inflammation in the brain, which is known to damage neurons and trigger dementia symptoms. Decrease in amyloid and tau proteins: GLP-1 agonists could suppress the accumulation of toxic proteins linked to Alzheimer's disease. Improved blood vessel health: They may reduce blood pressure and enhance blood flow, preventing vascular dementia. Neurogenesis stimulation: Early research suggests these drugs may promote neural growth in the hippocampus, the brain region essential for memory. GLP-1 drugs may help prevent both diabetes and dementia The new study aligns with earlier research from the University of Florida, which followed 400,000 Americans and reported a 33% lower risk of dementia among GLP-1 users compared to other treatments. This growing body of evidence supports the role of semaglutide and tirzepatide not only in treating type 2 diabetes and obesity but potentially in preventing cognitive decline. Professor Martin O'Donnell, Dean at the University of Galway, emphasised, 'With both diabetes and dementia rising, these findings have major public health implications.' Dementia and diabetes: Twin epidemics in the US The study arrives amid alarming trends: Over 8 million Americans currently live with dementia, with 500,000 new cases diagnosed each year. Diabetes now affects 38 million people in the US; around 12% of the population. According to the Alzheimer's Association, Alzheimer's rates have climbed 25 consecutive years. The intersection of these two epidemics highlights the urgency of therapies that can address both conditions simultaneously. Study highlights need for more GLP-1 brain health data While the findings are promising, researchers caution that more work is needed to confirm the results. Notable limitations include: Lack of data on dementia subtypes like Lewy body and vascular dementia Differences in study design and follow-up durations Unclear long-term cognitive outcomes for different age groups and genders Still, this analysis lays essential groundwork for future research into neurometabolic protection via GLP-1 therapies. Originally celebrated as breakthrough treatments for obesity and diabetes, these medications may now be poised to take on an even broader role in preventing neurodegenerative diseases. As Dr. Reddin concluded, 'This research marks a significant advancement in how we understand the brain benefits of diabetes medications.' This article is based on findings from a study published in JAMA Neurology (July 2024). While the research links GLP-1 drugs like Ozempic and Mounjaro to reduce dementia risk, it is observational and does not prove direct causation. Further studies are needed. Always consult a healthcare provider before making medication decisions. Also Read | 5 coffee routine habits that could be doing more harm than good, say experts
